Bruker CORP

Bruker Corporation announced second quarter 2026 financial results, showing a return to organic revenue growth and strong bookings, alongside a significant goodwill impairment charge impacting GAAP results.

Bruker Corporation announced its Board of Directors has declared a quarterly cash dividend for its 6.375% Mandatory Convertible Preferred Stock, Series A.

Bruker Corporation confirms the election of directors and approval of executive compensation at its 2026 Annual Meeting.

Bruker Corporation's 2026 Annual Meeting saw the election of Class II directors, approval of executive compensation, and ratification of its independent auditor.

Bruker Corporation announced first quarter 2026 financial results, with revenues of $823.4 million, and reaffirmed its full-year 2026 financial outlook.

Bruker Corporation announced its Board of Directors has declared a quarterly cash dividend for its Series A Mandatory Convertible Preferred Stock.

Bruker Corporation's Q2 2026 results show revenue growth but a net loss driven by substantial goodwill impairment charges, impacting overall financial performance.

Bruker Corporation reported a 2.7% increase in total revenue for the first quarter of 2026, reaching $823.4 million, driven by acquisitions and foreign exchange tailwinds, though operating income saw a significant decrease.

Bruker Corporation reported a significant net loss for Q3 2025, driven by goodwill and intangible asset impairment charges and declining revenue in key segments, despite a capital raise.

Bruker Corporation reports a significant drop in Q2 operating income and year-to-date net income, despite revenue growth from recent acquisitions, as it initiates a major cost-saving restructuring.

Bruker Corporation's Q1 2025 revenue increased by 11.0% year-over-year, but operating income decreased due to acquisition-related expenses.

Bruker Corporation's Q3 2024 results show revenue growth driven by acquisitions, but a decrease in profitability due to integration costs and other factors.

Bruker Corporation reported a net loss of $22.5 million for fiscal year 2025, a significant decline from the prior year, primarily due to goodwill impairment, increased tariffs, and foreign exchange headwinds, despite a 2.1% revenue increase.

Bruker Corporation's 2024 10-K filing reveals strategic acquisitions, supply chain hurdles, and a commitment to innovation in scientific instruments and analytical solutions.

Bruker Corporation's 2023 annual report reveals a significant revenue increase and strategic growth through acquisitions, despite some margin pressures.

Burkhard Prause, PRES. & CEO, BRUKER BEST of Bruker Corp, reported multiple transactions in common stock on August 15, 2026.

Wolfgang Pusch, President BMID Group of Bruker Corp, sold 3,473 shares of common stock on August 15, 2026 for $56.90 per share.

Frank H Laukien, PRESIDENT & CEO, a Director and 10% owner of Bruker Corp, reported a transaction in 4,838 shares of common stock on August 11, 2026.

Mark Munch, EXEC VP&PRES BRUKER NANO INC. of Bruker Corp, sold 2,000 shares of common stock on July 15, 2026 for $60.25 per share.

Mark Munch of Bruker Corp engaged in a Rule 10b5-1 trading plan, acquiring 2,000 shares at $22.19 and selling 2,000 shares at $54.76 on June 15, 2026.

Bruker Corporation director Thierry Bernard was granted 2,886 restricted stock units as part of his compensation package.

Bruker Corporation announces its 2026 Annual Meeting of Stockholders, to be held virtually on May 21, 2026, with key proposals including director elections and executive compensation.

Bruker Corporation is seeking stockholder approval for its 2026 Incentive Compensation Plan to replace the expiring 2016 plan, aiming to maintain competitive compensation practices and align employee interests with stockholders.

Bruker Corporation's 2023 Annual Meeting is scheduled for June 7, 2023, where shareholders will vote on important proposals.

Bruker Corporation announces its 2025 Annual Meeting of Stockholders to address director elections, executive compensation, auditor ratification, and a new 2026 Incentive Compensation Plan.

Bruker Corporation's upcoming annual meeting on June 7, 2023, will address key proposals outlined in the proxy statement.

Bruker Corporation's 2024 Annual Meeting of Stockholders will be held virtually on May 30, 2024, to vote on director elections, executive compensation, and the ratification of the independent accounting firm.

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, disclosing a beneficial ownership of 15.0% of Bruker Corp's common stock as of June 30, 2026.

Several investment management firms have collectively disclosed beneficial ownership of approximately 11.8% of Bruker Corp's common stock as of March 31, 2026.

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 12.4% in Bruker Corp's common stock as of March 31, 2026.

The Vanguard Group filed an amended Schedule 13G for Bruker Corp, reporting zero beneficial ownership following an internal realignment.

Orbis Investment Management and its affiliates have disclosed a combined beneficial ownership of 10.6% of Bruker Corp's common stock.

Orbis Investment Management Ltd, Allan Gray Australia Pty Ltd, and Orbis Investment Management (U.S.) L.P. collectively reported beneficial ownership of 9.8% of Bruker Corp's common stock.